COMMUNIQUÉS West-GlobeNewswire

Helio Genomics to Host In-Person & Virtual KOL Event in New York to Review Results from CLiMB Pivotal Trial Presented at EASL Congress 2024 on June 17, 2024
06/06/2024
IRVINE, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today [...]
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
06/06/2024
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed [...]
American Oncology Network Expands Radiation Oncology Services, Opens New Clinic
06/06/2024
Low Country Radiation in Waycross provides residents access to advanced radiation oncology care. FORT MYERS, Fla., June 06, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s [...]
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
06/06/2024
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
06/06/2024
TNX-1500 displays potential as a monotherapy or combination therapy to prevent rejection in organ transplantation in allograft and xenograft animal models Research Directed by Faculty of the Center for Transplantation [...]
Cytek Biosciences Announces $50 Million Stock Repurchase Program
06/06/2024
FREMONT, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an [...]
electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
06/06/2024
ROCKAWAY, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced the closing of its [...]
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
06/06/2024
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment [...]
OneMedNet Significantly Expands Industry Access to Proprietary iRWD™ Network and Platform by Joining AWS Partner Network
06/06/2024
Secures new life science company customer through this globally recognized and trusted new channel MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the [...]
Breckenridge Distillery Wins Double Gold for a Consecutive Year in a Row at the 2024 New York International Spirits Competition
06/06/2024
The Distillery is Now a Four-Time Winner For ‘Colorado American Blended Whiskey Distillery Of The Year’ and its Signature Port Cask Finish Continues to Receive Praise BRECKENRIDGE, Colo., June 06, 2024 (GLOBE NEWSWIRE [...]
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
06/06/2024
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today [...]
Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
06/06/2024
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that on June 4, 2024, it was notified by the [...]
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
06/06/2024
Clinically meaningful improvements in ppFEV 1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV 1 50-80%) and >6 months follow up Aerosolized 4D-710 was well [...]
Virbac : Declaration of the number of shares and voting rights 05/2024
06/06/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 05/2024
06/06/2024
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Cartesian Therapeutics Announces New Employment Inducement Grant
06/06/2024
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune [...]
Redecan Cannabis Introduces New Top Shelf Flower 'Purple Churro'
06/06/2024
The Tasty New Sativa Strain is Now Available Across Canada TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods [...]
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
06/06/2024
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today [...]
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
06/06/2024
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 [...]

Pages